micro-community-banner
  • Saved

1yr
An angel or a devil? Current view on the role of CD8+ T cells in the pathogenesis of myasthenia gravis

An angel or a devil? Current view on the role of CD8+ T cells in the pathogenesis of myasthenia gravis

Source : https://pubmed.ncbi.nlm.nih.gov/38378668/

Further studies on CD8 + T cells in MG are necessary to determine, among others, the real pattern of the Vβ gene usage of autoantigen-specific CD8 + cells in patients...

Further studies on CD8+ T cells in MG are needed to explore autoantigen-specific subsets, including Tc1, Tc17, and IL-17+IFN-γ+CD8+ T cells, and CD20+ and CXCR5+ CD8 T cells.

  • Saved

1yr
Advances in Understanding and Managing Myasthenia Gravis: Current Trends and Future Directions

Advances in Understanding and Managing Myasthenia Gravis: Current Trends and Future Directions

Source : https://pubmed.ncbi.nlm.nih.gov/38803727/

Myasthenia gravis (MG) is an autoimmune illness characterized by autoantibodies against the acetylcholine receptor (AChR), muscle-specific tyrosine kinase (MuSK), and an increasing number of extra postsynaptic proteins. Pathogenic autoantibodies reduce...

Myasthenia gravis is an autoimmune disorder causing muscle weakness, primarily due to autoantibodies targeting AChR. Treatment focuses on managing symptoms via immune modulation, including complement inhibition and plasmapheresis.

  • Saved

1yr
Strategies to improve autoimmune neurological diseases treatment - PubMed

Strategies to improve autoimmune neurological diseases treatment - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39299843/

There is a need to improve therapies in autoimmune neurologic conditions. Yet which strategic objectives are required, what are the barriers that stand before reaching them, and what are the...

Improving therapies for autoimmune neurologic conditions requires addressing strategic objectives, overcoming barriers, targeting autoantigens, and enhancing training for neuroimmunologists to advance treatment and understanding of these diseases.

  • Saved

1yr
Sugammadex and neuromuscular disease: a systematic review with assessment of reporting quality and content validity - PubMed

Sugammadex and neuromuscular disease: a systematic review with assessment of reporting quality and content validity - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38997841/

PROSPERO 2019 (CRD42019119924).

Current observational data, mostly of low to moderate quality, are insufficient to confidently assess the efficacy and safety of sugammadex for NMBA reversal in neuromuscular disease patients, highlighting the need for improved reporting.

  • Saved

1yr
Immunoglobulin National Society 2024: 13th Annual Conference

The Immunoglobulin National Society (IgNS) is hosting its 13th annual conference from Oct. 17 to 20, 2024, at the Gaylord National Resort & Convention Center in Washington, D.C.

The theme of this year’s conference is “Supporting Ig Clinicians and Business Professionals,” built upon the three pillars of education, networking, and advancement. The sessions will focus either on clinical practice or business and operations. Within each focus are three tracks: The clinical practice session will feature sessions on advanced practice, biologics/biosimilars, and clinical foundations; the business and operations track will cover payer guidelines, business operations practices, and information about accreditation.